Association between the cumulative dose of glucocorticoids before the development of pneumonia and death in patients receiving long-term glucocorticoids: a secondary analysis based on a Chinese cohort study

被引:1
作者
Guo, Hui-Jie [1 ]
Ye, Yi-Lu [2 ]
Cao, Rong [1 ]
Liu, Zhi-Hua [3 ]
He, Qun [1 ]
机构
[1] Guangdong Prov Ctr Dis Control & Prevent, Guangdong Prov Inst Publ Hlth, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 5, Dept Rehabil Med, Key Lab Biol Targeting Diag, Guangzhou, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Key, Guangzhou, Peoples R China
关键词
glucocorticoids; immunocompromised patients; pneumonia; case fatality risks; cohort study; PNEUMOCYSTIS-JIROVECII PNEUMONIA; PROGNOSTIC-FACTORS; CARINII-PNEUMONIA; RISK; INFECTION; MORBIDITY; MORTALITY;
D O I
10.3389/fmed.2023.1175855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe present study aimed to evaluate the association between the cumulative dose of glucocorticoids (GCs) and case fatality in hospitalized patients who developed pneumonia while receiving glucocorticoid therapy. MethodsThis retrospective cohort study included 625 patients receiving long-term GC treatment who were hospitalized with pneumonia (322 male and 303 female). Data were obtained from the Dryad Digital Repository and were used to perform secondary analysis. Multivariable Cox proportional hazard regression model and restricted cubic splines (RCS) were used to evaluate the association between the cumulative dose of GCs and case fatality. Sensitivity analyses and subgroup analyses were performed. ResultsThe 30-day and 90-day death rates were 22.9 and 26.2%, respectively. After adjusting for potential confounders, compared with those in the lowest quintile (& LE; 1.5 g), the Cox proportional hazard regression model analysis showed that patients with different cumulative doses of GCs (1.5 to 2.95, 2.95 to 5, 5 to 11.5, and > 11.5 g) had lower risks for 30-day death, with respective hazard ratios of 0.86 (95% CI, 0.52 to 1.42), 0.81 (0.49 to 1.33), 0.29 (0.15 to 0.55), and 0.42 (0.22 to 0.79). The multivariable-adjusted RCS analysis suggested a statistically significant N-shaped association between the cumulative dose of GCs and 30-day death. A higher cumulative dose of GC tended to first lead to an increase in 30-day death within 1.8 g, then to a statistically significant decrease until around 8 g [HR for 1 g = 0.82 (0.69 to 0.97)], and again to an increase afterward. Similar results were found in the subgroup analyses and sensitivity analyses. ConclusionN-shaped association between the cumulative dose of GCs and case fatality was observed in patients receiving long-term GC treatment who were hospitalized with pneumonia. Our findings may help physicians manage these patients.
引用
收藏
页数:10
相关论文
共 39 条
[1]   Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment -: Etiology, prognostic factors, and associated inflammatory response [J].
Agustí, C ;
Rañó, A ;
Filella, X ;
González, J ;
Moreno, A ;
Xaubet, A ;
Torres, A .
CHEST, 2003, 123 (02) :488-498
[2]   Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts [J].
Ajmal, Saira ;
Mahmood, Maryam ;
Abu Saleh, Omar ;
Larson, Jenifer ;
Sohail, M. Rizwan .
INFECTION, 2018, 46 (04) :555-558
[3]   Immunosuppressive burden and risk factors of infection in primary childhood nephrotic syndrome [J].
Alfakeekh, Khalid ;
Azar, Mohammed ;
Al Sowailmi, Banan ;
Alsulaiman, Saja ;
Al Makdob, Salwa ;
Omair, Aamir ;
Albanyan, Esam ;
Bawazeer, Manal Saleh .
JOURNAL OF INFECTION AND PUBLIC HEALTH, 2019, 12 (01) :90-94
[4]   Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV [J].
Asai, Nobuhiro ;
Motojima, Shinji ;
Ohkuni, Yoshihiro ;
Matsunuma, Ryo ;
Iwasaki, Takuya ;
Nakashima, Kei ;
Sogawa, Keiji ;
Nakashita, Tamao ;
Kaneko, Norihiro .
CHEMOTHERAPY, 2017, 62 (06) :343-349
[5]   Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis [J].
Broder, Michael S. ;
Sarsour, Khaled ;
Chang, Eunice ;
Collinson, Neil ;
Tuckwell, Katie ;
Napalkov, Pavel ;
Klearman, Micki .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (02) :246-252
[6]   Prevention of glucocorticoid morbidity in giant cell arteritis [J].
Buttgereit, Frank ;
Matteson, Eric L. ;
Dejaco, Christian ;
Dasgupta, Bhaskar .
RHEUMATOLOGY, 2018, 57 :11-21
[7]   Pneumocystis jirovecii Pneumonia in Patients With Autoimmune Disease on High-Dose Glucocorticoid [J].
Chew, Li-Ching ;
Maceda-Galang, Liza Marie ;
Tan, York Kiat ;
Chakraborty, Bibhas ;
Thumboo, Julian .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2015, 21 (02) :72-75
[8]   Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results [J].
Crim, C. ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Willits, L. R. ;
Yates, J. C. ;
Vestbo, J. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (03) :641-647
[9]   Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis [J].
del Rincon, Inmaculada ;
Battafarano, Daniel F. ;
Restrepo, Jose F. ;
Erikson, John M. ;
Escalante, Agustin .
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (02) :264-272
[10]   High Mortality Rate in Oral Glucocorticoid Users: A Population-Based Matched Cohort Study [J].
Einarsdottir, Margret J. ;
Ekman, Per ;
Molin, Mattias ;
Trimpou, Penelope ;
Olsson, Daniel S. ;
Johannsson, Gudmundur ;
Ragnarsson, Oskar .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13